Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

Arvinas (ARVN) announced on Tuesday that the company and its partner, Pfizer (PFE), reached an agreement with Rigel ...

April 29 (Reuters) - Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood ...

Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...

Arvinas and Pfizer have chosen Rigel Pharmaceuticals to bring their recently approved breast-cancer drug Veppanu to market.

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...

Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.